An observational study in Duchenne Muscular Dystrophy, sponsored by REGENXBIO Inc.. Active, not recruiting at 1 site in United States. Open to male participants aged 0 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-07-07.
Sponsored by REGENXBIO Inc. · Observational
This is an observational screening study to evaluate the prevalence of anti-adeno-associated serotype 8 (AAV8) antibodies in participants with Duchenne muscular dystrophy (DMD).
This is an observational screening study to evaluate the prevalence of anti-adeno-associated serotype 8 (AAV8) antibodies in participants with Duchenne muscular dystrophy (DMD). Information collected in this study may be used to identify potential participants for DMD investigational gene therapy clinical trials.
This study consists of:
473 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.
This study's planned enrollment of 200 is above the median of 60 across 130 observational studies indexed under Muscular Dystrophy, Duchenne.
Browse Muscular Dystrophy, Duchenne studies →REGENXBIO Inc. is the lead sponsor of 18 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Primary care clinic, Musculoskeletal care, Neuromusculoskeletal care
Exclusion Criteria:
An in vitro diagnostic assay to detect antibodies to AAV8 in human serum specimens.
Prevalence of anti-AAV8 antibodies in patients with DMD
* To evaluate the prevalence of AAV8 antibodies in patients with DMD * To identify participants who may be eligible for investigational gene therapy clinical trials in males with DMD
Time frame: 90 days
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
REGENXBIO Inc.